(Reuters) -Eli Lilly ( LLY ) has sent cease-and-desist letters to U.S. healthcare providers in recent days demanding they stop the promotion of copycat weight-loss drugs as the supply of its brand-name medicines improves, Bloomberg News reported on Wednesday.

Lilly now considers the brand-name drugs to be available and said compounded drugs from state-licensed facilities should not be sold anymore, the report added, citing a spokesperson.

The U.S. Food and Drug Administration recently listed all doses of Eli Lilly's ( LLY ) weight-loss drug Zepbound and diabetes drug Mounjaro as available, but did not remove them from the shortage list.

The health regulator and Eli Lilly ( LLY ) did not immediately respond to Reuters requests for comment.

The letters were sent to telehealth companies, wellness centers and medical spas, a spokesperson said, according to the report.

The report also said several brick-and-mortar clinics also received letters, according to interviews and records reviewed by Bloomberg.

The letters, signed by attorneys at Kirkland & Ellis LLP, command providers to stop the "manufacture, promotion, and/or sale" of compounded versions of Lilly's Mounjaro and Zepbound, Bloomberg said.